---
title: "LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286648897.md"
description: "LifeSci Capital analyst Francois Brisebois has maintained a Buy rating on Savara (SVRA) with a price target of $9.00. The overall analyst consensus for Savara is a Strong Buy, with an average price target of $11.00. Brisebois has a 40.11% success rate on his stock recommendations."
datetime: "2026-05-16T14:36:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286648897.md)
  - [en](https://longbridge.com/en/news/286648897.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286648897.md)
---

# LifeSci Capital Keeps Their Buy Rating on Savara (SVRA)

LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Savara today and set a price target of $9.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Brisebois covers the Healthcare sector, focusing on stocks such as Savara, Praxis Precision Medicines, and Opus Genetics. According to TipRanks, Brisebois has an average return of 2.4% and a 40.11% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Savara with a $11.00 average price target.

### Related Stocks

- [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PRAX.US](https://longbridge.com/en/quote/PRAX.US.md)
- [IRD.US](https://longbridge.com/en/quote/IRD.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Savara Q1 net loss widens on higher R&D costs](https://longbridge.com/en/news/286150721.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)